Galgo Medical, a Barcelona, Spain-based medical software company, raised €1m in public-private funding.
Backers included Inveready, which made the invested through its fund Inveready Innvierte Biotech II.
The company intends to use the funds to continue to develop, expand its marketing efforts of its three product lines, to strengthen the team, both technical and commercial, as well as open new headquarters in Singapore.
Led by Dr. Luis Serra, president, Galgo has a first product on the market in the field of orthoporosis, 3D-DXA Femur ™, which allows greater accuracy in the diagnosis and monitoring of osteoporosis. The product is already commercialized by the French manufacturer DMS (Montpellier, France).
In addition, the company is developing ADAS ™, a product focused on the characterization of the arrhythmia substrate for planning ventricle tachycardia interventions and predicting the risk of sudden death. The clinical validation is being performed in hospitals from the US, Brazil, Germany, Holland, Spain and Singapore.
Finally, it has a first prototype that allows neurosurgeons and interventional radiologist planning neurovascular device interventions, particularly stents.